0826 Freenome
BioCentury & Getty Images

Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round 

Company expanding pivotal trial as it assesses next indications

Freenome plans to develop additional blood-based cancer tests as its lead product, an early detection colorectal cancer diagnostic, enters pivotal testing.

Aug 27, 2020 | 2:16 AM GMT

Freenome’s $270 million series C will fuel the company’s push to move its multiomics cancer screening technology beyond colorectal cancer.

New investor Bain Capital Life Sciences and existing investor Perceptive Advisors led the untranched round, which brings Freenome’s total private funding to more than $500 million.

Read the full 974 word article

How to gain access

Continue reading with a
two-week free trial.